1. Clinical & Scientific Overview
Febuxostat (TIP-MED-000113, Reference Code [7.11]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.11], p. 84): Febutaz (Sun Pharma), Febuget (Sun), Zurig (Zydus), Uloric, Foxstat (Franco-Indian), Febumac (Macleods) — Strengths & Dosage Forms: Oral Film-Coated Tablets: 40 mg, 80 mg (also 20 mg in select brands)
Oral Film-Coated Tablets: 40 mg, 80 mg (also 20 mg in select brands)
3. Mechanism of Action & Pharmacodynamics
Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering Agent acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering Agent for Chronic management of hyperuricaemia in patients with gout (particularly in patients with mild-to-moderate CKD or allopurinol intolerance)..
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic management of hyperuricaemia in patients with gout (particularly in patients with mild-to-moderate CKD or allopurinol intolerance)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initially 40 mg once daily; if serum uric acid remains >6.0 mg/dL after 2–4 weeks, may increase to 80 mg once daily. Follow physician prescription.
Administration & Meal Timing: With or without food (nor affected by antacids). | Once daily in the morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Metabolised predominantly by hepatic UGT glucuronidation and oxidation (~50% excreted in faeces)—no dose adjustment required in mild-to-moderate CKD (eGFR 30–89 mL/min), making 40 mg OD widely used in CKD Stage 3 gout patients; in severe CKD (eGFR 15–29 mL/min), limit to 40 mg once daily. Hepatic: Monitor LFTs; avoid in severe hepatic impairment (Child-Pugh C).
Renal: Metabolised predominantly by hepatic UGT glucuronidation and oxidation (~50% excreted in faeces)—no dose adjustment required in mild-to-moderate CKD (eGFR 30–89 mL/min), making 40 mg OD widely used in CKD Stage 3 gout patients; in severe CKD (eGFR 15–29 mL/min), limit to 40 mg once daily. Hepatic: Monitor LFTs; avoid in severe hepatic impairment (Child-Pugh C).
Renal: Metabolised predominantly by hepatic UGT glucuronidation and oxidation (~50% excreted in faeces)—no dose adjustment required in mild-to-moderate CKD (eGFR 30–89 mL/min), making 40 mg OD widely used in CKD Stage 3 gout patients; in severe CKD (eGFR 15–29 mL/min), limit to 40 mg once daily. Hepatic: Monitor LFTs; avoid in severe hepatic impairment (Child-Pugh C).
7. Contraindications, Precautions & High-Risk Warnings
- Strictly CONTRAINDICATED with Azathioprine and 6-Mercaptopurine! Cardiovascular Boxed Warning (CARES Trial): Associated with a higher rate of cardiovascular death compared to allopurinol in patients with established major cardiovascular disease (prior MI, unstable angina, stroke)—use with caution or prefer properly titrated allopurinol in established IHD/stroke unless allopurinol is contraindicated.
Key Clinical Precautions: Renal: Metabolised predominantly by hepatic UGT glucuronidation and oxidation (~50% excreted in faeces)—no dose adjustment required in mild-to-moderate CKD (eGFR 30–89 mL/min), making 40 mg OD widely used in CKD Stage 3 gout patients; in severe CKD (eGFR 15–29 mL/min), limit to 40 mg once daily. Hepatic: Monitor LFTs; avoid in severe hepatic impairment (Child-Pugh C).
8. Adverse Effects Profile
- Hepatic transaminase elevation (ALT/AST), nausea, arthralgia, acute gout flares during initial 1–6 months (due to rapid urate mobilisation—co-prescribe low-dose colchicine or NSAID prophylaxis), rash.
- Cardiovascular thromboembolic events / sudden cardiac death in high-risk cardiac patients, severe hepatotoxicity/jaundice, rare DRESS / Stevens-Johnson syndrome (lower rate than allopurinol, though caution still required in prior allopurinol SJS).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- ABSOLUTELY CONTRAINDICATED with Azathioprine (Azoran) and 6-Mercaptopurine (blocks xanthine oxidase degradation -> fatal myelosuppression!)
- Increases theophylline levels mildly
- Safe with warfarin and hydrochlorothiazide
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Explain that Febuxostat is NOT a painkiller (do not take it SOS only when the toe hurts!). Taking it daily lowers uric acid, and during the first few months, dissolving crystals may trigger temporary joint flares—continue taking Febuxostat daily even if a gout flare occurs. Report chest pain, shortness of breath, rash, or yellowing of the eyes immediately.
- Meal & Clock Timing Instruction: With or without food (nor affected by antacids). (Once daily in the morning.)
- Missed Dose Protocol: Take as soon as remembered on the same day; skip if close to next day's dose.
- Geriatric Dispensing Pearl: In elderly CGHS patients with established coronary artery disease or prior stroke, flag high-dose Febuxostat (80 mg) for physician review; ensure 40 mg OD is not exceeded in Stage 4 CKD and verify the patient is not taking Azathioprine.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 40 mg, 80 mg (also 20 mg in select brands)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.11] (p. 84)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.13] Thiocolchicoside, Tolperisone Hydrochloride & Chlorzoxazone (Spinal & Central Muscle Relaxants) — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
- [7.14] Piroxicam & Meloxicam — Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2
- [7.15] Ketorolac Tromethamine — Potent Pyrrolizine Carboxylic Acid Non-Selective COX Inhibitor An
- [7.16] Mefenamic Acid — Anthranilic Acid (Fenamate) COX-1 / COX-2 Inhibitor & Prostagland
